Ganaxolone

Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering

Retrieved on: 
Tuesday, November 8, 2022
Pharmaceutical, Health, Other Health, Food, IV, GABAA, Park Avenue, News, Medication, U.S. Securities and Exchange Commission, RBC Capital Markets, Patient, Form, SEC, Private Securities Litigation Reform Act, Brain, Epilepsy, Attention, Telephone, No, Vesey Street, Forward-looking statement, CV, Equity capital markets, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prospectus, LLC, The Women on the 6th Floor, Form S-3, State Street, Investment, Public expenditure, Ganaxolone, CDKL5, Marinus, Research, Seizure, Security (finance), Therapy, Sale, Adult, Pharmaceutical industry

In addition, Marinus has granted the underwriters a 30-day option to purchase up to 1,894,737 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Marinus has granted the underwriters a 30-day option to purchase up to 1,894,737 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on November 10, 2022, subject to satisfaction of customary closing conditions.
  • SVB Securities, RBC Capital Markets and Cantor Fitzgerald & Co. are acting as joint bookrunners for the offering.
  • Uncertainties and risks may cause Marinus actual results to be materially different than those expressed in or implied by Marinus forward-looking statements.

Marinus Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Food, IV, GABAA, Park Avenue, News, Medication, U.S. Securities and Exchange Commission, RBC Capital Markets, Patient, Form, SEC, Private Securities Litigation Reform Act, Brain, Epilepsy, Attention, Telephone, No, Vesey Street, Forward-looking statement, CV, Equity capital markets, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prospectus, LLC, The Women on the 6th Floor, Form S-3, State Street, Investment, Public expenditure, Ganaxolone, CDKL5, Marinus, Research, Seizure, Security (finance), Therapy, Sale, Adult, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities.
  • In addition, Marinus expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of securities offered in the public offering at the public offering price, less underwriting discounts and commissions.
  • SVB Securities, RBC Capital Markets and Cantor Fitzgerald & Co. are acting as joint bookrunners for the proposed offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ESE, Marketing, Biomedical Advanced Research and Development Authority, IV, PRV, European Directive on Traditional Herbal Medicinal Products, Medication, U.S. Securities and Exchange Commission, Growth, Patient, Human services, Company, EMA, BARDA, Orion Corporation, Administration, Office of Inspector General, U.S. Department of Health and Human Services, Epilepsy, Ovid, Orion, RAISE, RSE, European Medicines Agency, Goal, Prodrug, API, CDD, Status epilepticus, Ganaxolone, SG, CDKL5, Research, Marinus, Patent, MAA, Development, R, Therapy, Security (finance), Sale, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmaceutical industry, Health insurance, Fine chemical, Cryptocurrency

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2022.
  • We believe we are poised to execute on our goals and expand our reach to additional patients suffering from rare forms of epilepsy.
  • Collaboration revenue in 2022 consists of a one-time revenue recognition of $12.7 million in the first quarter of 2022 related to the Orion collaboration.
  • The Company reported net income of $73.3 million and $14.5 million for the three and nine months ended September 30, 2022, respectively.

Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners

Retrieved on: 
Monday, October 31, 2022
Health, Pharmaceutical, Morgan Stanley, U.S. Securities and Exchange Commission, Brain, Private Securities Litigation Reform Act, Culture, Forward-looking statement, Patient, IV, Tuberous sclerosis, Adult, CDKL5, Clinical trial, Marinus, Company, EMA, Security (finance), Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Medication, FDA, Epilepsy, Ganaxolone, CV, Seizure, GABAA, Ecosystem, Achievement, COVID-19, Therapy, Pharmaceutical industry, Sagard

The total amount payable by Marinus to Sagard is capped at 1.9x of the upfront payment, with the ability to redeem the revenue interest financing agreement at lower multiples within the first four years from funding.

Key Points: 
  • The total amount payable by Marinus to Sagard is capped at 1.9x of the upfront payment, with the ability to redeem the revenue interest financing agreement at lower multiples within the first four years from funding.
  • Upon achievement of the cap amount, the revenue interest financing agreement will terminate.
  • Sagard is excited to complete this transaction with Marinus and help support the ongoing launch of ZTALMY and the development of ganaxolone, said Raja Manchanda, Partner at Sagard.
  • As a firm, Sagard operates platforms that invest across five asset classes: venture capital, private equity, private credit, real estate and healthcare royalties.

Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022

Retrieved on: 
Tuesday, October 25, 2022
Pharmaceutical, Health, Neurology, Clinical Trials, Medication, Epilepsy, Ganaxolone, Patient, Company, Brain, Therapy, CDKL5, Webcast, CV, Seizure, Adult, Pharmaceutical industry

The Company will host a conference call at 8:30 a.m. Eastern Time on November 8, 2022.

Key Points: 
  • The Company will host a conference call at 8:30 a.m. Eastern Time on November 8, 2022.
  • Participants may access the conference call via webcast on the Investor page of Marinus website at ir.marinuspharma.com/events-and-presentations .
  • An archived version of the call will be available approximately two hours after the completion of the event on the website.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, October 14, 2022
General Health, Neurology, Other Health, Health, Pharmaceutical, Cyprus Securities and Exchange Commission, Therapy, CV, Employment, Epilepsy, Patient, IV, GABAA, Financial compensation, Security (finance), Common stock, Seizure, Private Securities Litigation Reform Act, Company, CDKL5, Board, Adult, Medication, Ganaxolone, Brain, Forward-looking statement, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 46,999 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Retrieved on: 
Tuesday, October 11, 2022
Health, General Health, Time, Therapy, CV, Epilepsy, Patient, IV, GABAA, Seizure, CDKL5, Adult, 2021 Essex County Council election, Medication, Ganaxolone, Brain, Date, NTS Sessions 1–4, Pharmaceutical industry, Communications satellite

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October.
  • The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus.
  • Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects.
  • It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

Retrieved on: 
Thursday, September 22, 2022
Pharmaceutical, Health, Neurology, Biometrics, Adult, Organophosphate, Therapy, RAISE, Safety, Development, IV, COVID-19, Epilepsy, Seizure, GABAA, Brain, FDA, Office of Inspector General, U.S. Department of Health and Human Services, BARDA, Ganaxolone, Administration, Lists of weapons, Private Securities Litigation Reform Act, Forward-looking statement, SE, U.S. Securities and Exchange Commission, Status epilepticus, Patient, Clinical trial, U.S. Department of Defense Strategy for Operating in Cyberspace, Benzodiazepine, Human services, Medication, API, Biomedical Advanced Research and Development Authority, Security (finance), CDKL5, EMA, CV, Pharmaceutical industry, RSE

This contract option was exercised under Marinus ongoing cost-share contract with BARDA awarded in 2020 to support the development of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE).

Key Points: 
  • This contract option was exercised under Marinus ongoing cost-share contract with BARDA awarded in 2020 to support the development of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE).
  • Refractory status epilepticus is a life-threatening condition in which a significant number of patients do not respond to first- and second-line anticonvulsant drugs.
  • Ganaxolone development in the RAISE trial is being funded in part with federal funds from BARDA under contract number 75A50120C00159.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, September 9, 2022
General Health, Neurology, Other Health, Health, Pharmaceutical, Medication, CDKL5, GABAA, IV, Company, Therapy, Common stock, Brain, Adult, Private Securities Litigation Reform Act, Cyprus Securities and Exchange Commission, Forward-looking statement, CV, Board, Seizure, Security (finance), Financial compensation, Ganaxolone, Epilepsy, Employment, Patient, Pharmaceutical industry

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to nine new employees.

Key Points: 
  • (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to nine new employees.
  • The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 68,050 shares of its common stock (the Common Stock) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Patient, CDKL5, CV, IV, Seizure, Brain, Medication, GABAA, Conference, Therapy, Adult, Investor, Ganaxolone, Epilepsy, Pharmaceutical industry

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate in the following investor conferences in September.

Key Points: 
  • Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate in the following investor conferences in September.
  • H.C. Wainwright 24th Annual Global Investment Conference (New York, NY) on Wednesday, September 14 at 12:00 p.m.
  • Links to each event can be accessed on the Investors & Media page of Marinus website at ir.marinuspharma.com/events-and-presentations .
  • Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders.